• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc. (Amendment)

    2/10/22 9:01:58 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELDN alert in real time by email
    SC 13G/A 1 p22-0551sc13ga.htm ELEDON PHARMACEUTICALS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Eledon Pharmaceuticals, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)
     

    28617K101

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 11 Pages)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 28617K10113G/APage 2 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 28617K10113G/APage 3 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 28617K10113G/APage 4 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 28617K10113G/APage 5 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 28617K10113G/APage 6 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 28617K10113G/APage 7 of 11 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Eledon Pharmaceuticals, Inc.(the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 19900 MacArthur Blvd., Suite 550, Irvine, California 92612.
       
    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:
       
      (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”) with respect to the shares of Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson (“Mr. Atchinson”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and
       
      (v) Phillip Gross (“Mr. Gross”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    CUSIP No. 28617K10113G/APage 8 of 11 Pages

     

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, $0.001 par value per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      28617K101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with
    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with
    Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

     

    CUSIP No. 28617K10113G/APage 9 of 11 Pages

      

    Item 4. OWNERSHIP

     

      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  0
        (b) Percent of class: 0%.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote: 0
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  0

     

    ACP has the power to dispose of and the power to vote the shares of Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP’s operations. Neither ACPGP nor ACA directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  0
        (b) Percent of class:  0%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  0
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  0

     

    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the shares of Common Stock beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
     

    If this statement is being filed to report the fact that as of the date

    hereof the Reporting Persons have ceased to be the beneficial owner of more than

    five percent of the class of securities, check the following: ☒

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

     

    CUSIP No. 28617K10113G/APage 10 of 11 Pages

     

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.
       
    Item 10. CERTIFICATION
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 28617K10113G/APage 11 of 11 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 10, 2022

     

    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL ADVISORS, L.L.C.  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ROBERT ATCHINSON  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    PHILLIP GROSS  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

     

    Get the next $ELDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELDN

    DatePrice TargetRatingAnalyst
    6/18/2025$9.00Buy
    H.C. Wainwright
    1/28/2025$9.00Buy
    Guggenheim
    5/13/2022$25.00 → $15.00Overweight
    Cantor Fitzgerald
    11/24/2021$35.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ELDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the m

    2/5/26 4:10:11 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

    Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss,

    1/23/26 7:00:00 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

    Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidney into a human at Massachusetts General Hospital Completed $57.5 million financing, with funds expected to support operations into 2Q 2027 IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE)

    1/8/26 4:05:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lee June converted options into 3,430 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:04 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcbride John S. converted options into 3,430 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:10 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Katkin Keith converted options into 8,575 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    1/16/26 5:00:06 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

    4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    5/13/24 5:04:15 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    SEC Filings

    View All

    Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    1/2/26 4:30:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    11/14/25 5:11:57 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.

    10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    11/14/25 5:05:47 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Eledon Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    6/18/25 7:57:38 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    1/28/25 7:12:35 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

    Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously

    5/13/22 9:03:12 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Leadership Updates

    Live Leadership Updates

    View All

    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

    Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera

    3/28/24 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  Dosed first participants in Phase 2 BESTOW trial in kidney transplantation  Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i

    1/4/24 4:40:44 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

    Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno

    11/9/23 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Financials

    Live finance-specific insights

    View All

    Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

    Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²  Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Conference call to be held Friday, November 7 at 8:00 a.m. ET IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced results from it

    11/6/25 6:30:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

    IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced an oral presentation will be featured at the American Society of Nephrology's upcoming Kidney Week 2025 Annual Meeting taking place in Houston, TX, from November 5-8, 2025. The oral presentation will highlight topline results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the oral presentation are below: Title:  Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW TrialPresenter:  Andrew Adams, M.D., Ph.D., Professor of Sur

    10/17/25 7:00:00 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubar

    8/6/25 4:01:00 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/14/24 4:51:31 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 4:17:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    11/5/24 11:44:57 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care